Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator
British Journal of Clinical Pharmacology2016Vol. 83(2), pp. 370–380
Citations Over TimeTop 16% of 2016 papers
Daphne Williams, Xiaolu Tao, Li Zhu, M. Stonier, Justin D. Lutz, Eric Masson, Sean X. Zhang, Bishu Ganguly, Zoe Tzogas, Susan Lubin, Bindu Murthy
Abstract
Therefore, no dose adjustments of CYP substrates are indicated with belatacept coadministration.
Related Papers
- Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers.(1987)
- → Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat.(1995)60 cited
- Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs.(1994)
- Pharmacological profile of dextrorphan.(1995)
- Comparative pharmacokinetics of oral dextromethorphan and dextrorphan in the rabbit.(1993)